Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Usana Health SciencesSTU:USJ -1.56%67 Days Payable is 25.54 as of Mar. 2026, which is 14% above its 10-year median of 22.49. GuruFocus rates STU:USJ with a GF Score™ of 67/100 and a GF Value™ of €35.51 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 1,891 Consumer Packaged Goods companies, Usana Health Sciences ranks worse than 72.4% on this metric.
Usana Health Sciences Days Payable Historical Data
* Premium members only.
The historical data trend for Usana Health Sciences's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:USJ vs NATR, ENHA, BYND: Days Payable Comparison
For the Packaged Foods subindustry, Usana Health Sciences's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Usana Health Sciences Days Payable vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Usana Health Sciences's Days Payable distribution charts can be found below:
* The bar in red indicates where Usana Health Sciences's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Usana Health Sciences's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Usana Health Sciences (STU:USJ) has a Days Payable of 25.54 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Usana Health Sciences and its competitors. This is 14% above median its historical median of 22.49. Over the past decade, Usana Health Sciences' Days Payable has ranged from 19.33 to 28.65. According to the industry distribution chart, Usana Health Sciences ranks #1369 out of 1891 companies in the Consumer Packaged Goods industry, placing it in the top 72.4%.
Is Usana Health Sciences' Days Payable too high?
Usana Health Sciences' current Days Payable of 25.54 is 14% above median its 10-year median of 22.49. Over the past 10 years, this metric has ranged from a low of 19.33 to a high of 28.65. The Consumer Packaged Goods industry median Days Payable is 44.15. Usana Health Sciences' value of 25.54 is 42.2% below this industry median. Based on the distribution chart, Usana Health Sciences ranks #1369 out of 1891 companies in the Consumer Packaged Goods industry, which is below the industry midpoint. Overall, Usana Health Sciences has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Usana Health Sciences' Days Payable compare to NATR and ENHA?
According to the Consumer Packaged Goods industry distribution chart, Usana Health Sciences ranks #1369 out of 1891 companies for Days Payable. This places Usana Health Sciences in the lower half of its industry. The industry median Days Payable is 44.15. Usana Health Sciences' value of 25.54 is 42.2% below this benchmark. Historically, Usana Health Sciences' own Days Payable has ranged from 19.33 to 28.65 over the past decade. While the company's 10-year median is 22.49 vs. the industry median of 44.15, Usana Health Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Consumer Packaged Goods company?
The median Days Payable among Consumer Packaged Goods companies is 44.15, based on 1,891 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Usana Health Sciences's current Days Payable of 25.54 is 42.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Usana Health Sciences and its competitors. For the Consumer Packaged Goods industry, the median Days Payable is 44.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Usana Health Sciences's current Days Payable is 25.54, which is 14% above median its own 10-year median of 22.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Usana Health Sciences stock overvalued right now?
Based on GuruFocus' analysis, Usana Health Sciences (STU:USJ) is currently considered Possible Value Trap. The stock's GF Value™ is €35.51, compared to a current price of €18.90 — trading 46.8% below its estimated fair value. The current Days Payable is 25.54, which is 14% above median its 10-year median of 22.49 and 42.2% below the Consumer Packaged Goods industry median of 44.15. Usana Health Sciences' overall GF Score™ is 67/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Usana Health Sciences (STU:USJ), the current Days Payable is 25.54 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Usana Health Sciences (STU:USJ) Overvalued in 2026?
Based on GuruFocus' analysis, Usana Health Sciences stock appears to be undervalued.
The current stock price of €18.90 is trading 46.8% below its estimated GF Value™ of €35.51.
GuruFocus considers Usana Health Sciences to be Possible Value Trap.
Key valuation signals for STU:USJ:
Days Payable: 25.54 (14% above median its 10-year median of 22.49)
GF Value™: €35.51 vs. price of €18.90 (46.8% below fair value)
Industry Position: 42.2% below the Consumer Packaged Goods median (#1369 of 1891)
No single metric tells the full story. See the STU:USJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Usana Health Sciences Inc develops and manufactures high-quality nutritional supplements, functional foods, and personal care products that are sold throughout the world. The company has developed and manufactured high-quality, science-based nutritional, personal care, and skincare products with a primary focus on promoting long-term health and wellness. The Company's reporting units for goodwill purposes are tied to its reportable segments: Core nutritional and Hiya direct-to-consumer. The core nutritional segment consists of three individual reporting units that are determined based on the operational nature of the business: Buy-Sell, China, and India. Geographically, it is in Asia Pacific, the Americas, and Europe. With the majority of revenue from Asia Pacific(Greater China).
67GF Score
Get the complete analysis for STU:USJ
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:USJ has been successfully added to your 
